Categories
Blood Cancer

The role of checkpoint inhibitors in classical Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes the efficacy of checkpoint inhibitors in treating classical Hodgkin lymphoma, which is the current standard of care in patients who have progressed from autologous stem cell transplantation. Multiple trials have demonstrated durable responses in patients receiving checkpoint inhibitors such as pembrolizumab with ICE or GVD chemotherapy and nivolumab with brentuximab vedotin as a salvage regimens. Further research will additionally reveal the potential of checkpoint inhibitors in the frontline setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Peak ALC after CAR-T infusion predicts clinical response in aggressive lymphoma [Video]

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the association between peak absolute lymphocyte count (ALC) after CAR-T infusion and clinical response in aggressive lymphoma. A higher absolute lymphocyte ALC peak was associated with increased complete response rates and a longer duration of response in the first 6 months post-CAR-T cell infusion. Increasing ALC levels also correlated with CAR-T cell expansion and higher rates of progression-free survival (PFS) and overall-survival (OS). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Outcomes of classic HL, relapsed within one year of diagnosis, in the era of novel agents [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses outcomes of primary refractory disease and early relapse in patients with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) treated with salvage therapy and autologous stem cell transplant (ASCT). Patients who relapsed within 1 year of diagnosis were highly likely to receive more than one line of salvage regimen before stem cell transplant, and they were less likely to be successfully bridged after 1 line of salvage therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma [Video]

In this discussion, leading experts Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, Suzanne Trudel, MD, MSc, Princess Margaret Cancer Centre, Toronto, Canada, and Frederick Locke, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, share their highlights from the lymphoma and myeloma sessions that took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL. The experts share their excitement for the practice-changing trial data demonstrating the benefit of CAR-T therapy in second line in large B-cell lymphoma (LBCL), as well as for the possibility of approaching a cure in follicular lymphoma (FL). They then move on to discuss strategies to overcome the challenges associated with CAR-T therapy in multiple myeloma, including allogeneic CAR-Ts, where they discuss emerging data on various allogeneic CAR-T products. The experts then comment on the potential of bispecific antibodies in myeloma and how patients might be selected to receive BCMA-directed CAR-T therapy or bispecific antibodies in the future. Finally, the experts discuss real-world data on CAR-T therapy for mantle cell lymphoma (MCL) and multiple myeloma.

Categories
Prostate Cancer

Disparities in clinical trial participation of ethnic minorities & older adults with prostate cancer [Video]

Irbaz Riaz, MBBS, MS, Mayo Clinic, Rochester, MN, discusses a study in which the disparities in clinical trial participation of both racial/ethic minority patients and older patients with prostate cancer were studied across the last 30 years. Black representation in prostate cancer clinical trials is less than 50% of their expected share based on cancer incidence. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Categories
Blood Cancer

Update on Phase II study of MGTA-145 + plerixafor for stem cell mobilization in multiple myeloma [Video]

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, gives an overview of the design and preliminary results of a Phase II study assessing the efficacy of MGTA-145, a novel CXCR2 agonist, in combination with plerixafor in mobilizing hematopoietic stem cells (HSCs) in transplant-eligible patients with multiple myeloma (NCT04552743). The study reported a manageable toxicity profile, with pain being the most common side effect, and 88% of patients met the primary endpoint of collecting two million CD34+ cells/kg. In addition, preliminary data show promising results in terms of engraftment success and durability. Dr Sidana explains that this new stem cell mobilization method offers several advantages in comparison to other existing strategies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The relevance of SCT in multiple myeloma [Video]

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the role of stem cell transplantation (SCT) in multiple myeloma, highlighting data from key clinical trials. The benefit of upfront SCT has been shown on multiple occasions and notably in the IFM 2009 trial (NCT01191060), which demonstrated that upfront transplant led to deeper measurable residual disease (MRD) negativity and longer progression-free survival (PFS). In addition, the FORTE trial comparing carfilzomib plus lenalidomide plus dexamethasone (KRd) followed by autologous stem cell transplantation (ASCT) and maintenance therapy versus KRd alone followed by maintenance therapy showed a superior PFS for both standard and high-risk patients undergoing early transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

An update on antibody-based treatment approaches in multiple myeloma [Video]

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, gives an update on antibody-based treatment approaches for patients with multiple myeloma. Monoclonal antibodies such as daratumumab and isatuximab have been approved for the treatment of relapsed myeloma for several years. Recent data from ASH on the GRIFFIN (NCT02874742) and GMMG HD7 (NCT03617731) trials are showing promising results for these two drugs in quadruplet regimens in the frontline setting. Bispecific antibodies are another exciting area of research in multiple myeloma, with agents including teclistamab, talquetamab, and cevostamab, who have been shown to induce response rates (RRs) averaging 60-70% in heavily pre-treated populations, and are associated with less frequent and less severe side effects than chimeric antigen receptor (CAR) T-cell therapy. These agents are expected to be approved in the upcoming years, which will broaden the therapeutic landscape for heavily pre-treated patients with multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The influence of bridging therapy on outcomes in large B-cell lymphoma [Video]

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the use of bridging therapy in a real world setting for patients with large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy. Stabilization of disease prior to treatment is associated with improved patients outcomes, independent of type of bridging therapy. However, investigational use of polatuzumab vedotin with rituximab and bendamustine as bridging therapy did not result in superior outcomes compared to other bridging regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Meta-analysis of cilta-cel in patients with R/R multiple myeloma [Video]

Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines [Video]

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of a study investigating optimal treatment sequencing in multiple myeloma. With the available options for treatment expanding rapidly, determining the best strategies for upfront treatment and subsequent lines of therapy is of critical importance. In this analysis, the clinical value of daratumumab (DARA) first line compared to later lines was examined in patients with newly diagnosed transplant-ineligible multiple myeloma, since it is unclear where it performs optimally. It was shown that using DARA, lenalidomide, and dexamethasone (D-Rd) first line substantially improved overall survival compared with delaying DARA-based treatment until second line. Due to higher attrition rates in second line and beyond, the results demonstrate that achieving the longest possible progression-free survival in first line is key to optimize overall survival outcomes and therefore, saving DARA to later lines is a suboptimal approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.